Inhalation Surfactant Therapy within Comprehensive Treatment of HIV-Infected Patients with Multiple Drug Resistant Tuberculosis

The objective: to evaluate the main eff ects of surfactant inhalations during the intensive phase of chemotherapy with the regimen containing bedaquiline and linezolid in HIV-infected patients with multiple drug resistant tuberculosis.

Subjects and Methods. A single-center, open-label, controlled prospective cohort study was conducted. 80 patients with MDR-TB/HIV were enrolled in the study and randomized into two groups: ST+ Group included 40 patients who in addition to anti-tuberculosis therapy containing bedaquiline and linezolid during the intensive phase received inhalation of the suspension of Surfactant-BL according to a certain regimen. The course of 28 inhalations took 2 months, the total dose of surfactant was 700 mg. ST- Group included 40 patients who received anti-tuberculosis therapy only. To assess the severity of respiratory symptoms in patients, we used our own scoring. All patients also received antiretroviral therapy.

Results. In the ST+ Group versus ST- Group, there was a decrease in the severity of tuberculosis clinical manifestations and timing of their relief, higher frequency of cavity healing by 21.2%, and faster sputum conversion by 28.6%. These rates are higher than in ST- Group and this is a short period of 10 weeks. None of the patients developed adverse reactions to surfactant inhalations. Patients tolerated well the combination of surfactant therapy, MDR TB chemotherapy containing bedaquiline and linezolid, and ART.

1. Borodulina E.A., Borodulin B.E., Tsygankov I.A., Chernogaeva G.Yu. Surfactant therapy in developing severe respiratory insufficiency in tuberculosis patients with concurrent HIV infection. Tuberculosis and Lung Diseases, 2015, pp. 34-37. (In Russ.)

2. Vasilyeva I.A., Samoylova A.G., Zimina V.N., Lovacheva O.V., Abramchenko A.V. Chemotherapy for tuberculosis in Russia – the story continues. Tuberculosis and Lung Diseases, 2023, vol. 101, no. 2, pp. 8-12. (In Russ.) https:// doi.org/10.58838/2075-1230-2023-101-2-8-12.

3. Golubinskaya E.P., Filonenko T.G., Ermola Yu.A., Kubyshkin A.V., Kalfa M.A. Immunohistochemical assessment of surfactant-associated proteins SP-B and SP-C in fibrous cavernous pulmonary tuberculosis. Meditsinsky Vestnik Bashkortostana, 2019, vol. 14, no. 3, pp. 41-46. (In Russ.)

4. Erokhin V.V., Lepekha L.N., Erokhin M.V., Lovacheva O.V. Surfaktantnaya sistema legkikh pri tuberkuleze. [Lung surfactant system in tuberculosis]. Moscow, New Terra Publ., 2013, 260 p.

5. Erokhin V.V., Lovacheva O.V., Lepekha L.N., Vasilyeva I.A., Bagdasaryan T.R., Rosenberg O.A. Kompleksnoe lechenie destruktivnogo tuberkulyoza lyogkikh s ispolzovaniem preparata prirodnogo surfaktanta «surfaktantB L»: Metod. rekomendatsii. [Comprehensive treatment of destructive tuberculosis with the use of natural surfactant of Surfactant-BL: Guidelines]. 2010, 22 p.

6. Erokhin V.V., Romanova L.K. Surfaktantnaya sistema legkikh. V kn. Kletochnaya biologiya lyogkikh v norme i pri patologii. Rukovodstvo dlya vrachey. [Lung surfactant system. In: Cellular biology of the lungs in health and pathology. Guidelines for doctors]. Moscow, Meditsina Publ., 2000, pp. 167-181.

7. Zhemkov V.F., Ivanovsky V.B., Zhemkova M.V. et al. Use of natural pulmonary surfactant in the complex treatment of pulmonary tuberculosis. Tuberculosis and Lung Diseases, 2013, no. 2, pp. 18-22. (In Russ.)

8. Lovacheva O.V., Chernichenko N.V., Evguschenko G.V. et al. Results of surfactant use for complex treatment of destructive pulmonary tuberculosis patients. Problemy Tuberkuleza i Bolezni Legkikh, 2006, no. 10, pp. 12-17. (In Russ.)

9. Osnovnye pokazateli protivotuberkuleznoy deyatelnosti v Sibirskom i Dalnevostochnom federalnykh okrugakh (statisticheskiye materialy). [Main rates of anti-tuberculosis activities in Siberian and Far Eastern Federal Districts (statistic materials)]. Novosibirsk, 2022, 105 p.

10. Rozenberg O.A., Lovacheva O.V., Shapovalov K.G., Akulova E.A., Stepanova O.V., Seyliev A.A., Shulga A.E. Surfactant therapy as a part of comprehensive treatment of asthma patients. Impact on clinical signs and external respiration rates. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 9, pp. 23-30. (In Russ.) 11. Sigaev A.T., Lovacheva O.V., Turovtseva Yu.V., Sivokozov I.V. Assessment of mucociliary clearance in pulmonary tuberculosis patients and its management

11. by surfactant therapy. Tuberculosis and Lung Diseases, 2011, no. 10, pp. 33-37. (In Russ.)

12. Tuberkulez u vzroslykh. Klinicheskie rekomendatsii. [Tuberculosis in adults. Guidelines]. Moscow, 2022, 151 p. https://cr.minzdrav.gov.ru/recomend/16_2

13. Yablonskiy P.K., Granov A.M., Erokhin V.V., Zhemkov V.F. Surfactant therapy in the integral treatment of pulmonary tuberculosis. Russkiy Journal, SDID, Rak i Obschestvennoye Zdorovie, 2010, vol. 14, no. 1, pp. 41-42. (In Russ.)

14. Yerokhin V.V., Chernichenko N.V., Lepeha L.N., Lovacheva O.V. et al. Peculiarities of macrophagal composition of bronchial washings in destructive ТВ patients after using surfactant-BL (S-BL). Eur. Respir. J., 2003, no. 22, suppl. 40, pp. 340.

15. Golubinskaya E.P., Filonenko T.G, Zinchenko A.A. Dependence of sclerotic processes on macrophage activity in fibrous-cavernous tuberculosis. Synergy of Sciences, 2017, no. 8, pp. 527-532.

16. Iwaarden F.J., van van Golde L, M.J. Pulmonary surfactant and lung defense. In: Robertson B., Taeusch H.W. (eds.). Surfactant therapy for lung disease. Lung biology in health and disease. vol. 84, New York, Marcel Dekker Inc, 1995. pp. 75-84.

17. Lovacheva O.V., Chernichenko N.V., Lepeha L.N. et al. Use of surfactant-BL (S-BL) in complex treatment of pulmonary ТВ patients. Eur. Respir. J., 2003, no. 22, pp. 521-521.

18. Pushkareva E., Kolpakova Т. Analysis of medical and social factors of TB/HIV in the Siberian Federal District, the city of Novosibirsk and the region. European Respiratory Journal, 2020, vol. 56, pp. 1677. doi:10.1183/13993003

19. Rozenberg O.A. Pulmonary surfactants for acute and chronic lung diseases (Part II). Gen Reanimatol., 2014, vol. 10, no. 5, pp. 69-86.

20. Takano H. Pulmonary surfactant itself must be a strong defender against SARS-CoV-2. Med. Hypotheses, 2020, no. 144, 110020.

21. Raffetseder J., Iakobachvili N., Loitto V., Peters P. J., Lerm M. Retention of EsxA in the capsule-like layer of mycobacterium tuberculosis is associated with cytotoxicity and is counteracted by lung surfactant. Infect. Immun. 2019, 87 (3): e00803-18. Doi: 10.1128/IAI.00803-18. PMID:30602503; PMCID: PMC6386552.

22. Zhao J.W., Jiao L., Guo M.M., Zheng L., Wang X.B., Gao S.H., Ying B.M., Ming L. SFTPC genetic polymorphisms are associated with tuberculosis susceptibility and clinical phenotype in a Western Chinese Han population. Exp. Ther. Med., 2020, Nov., vol. 20(5), 100. doi: 10.3892/etm.2020.9230.Epub. 2020 Sep 17. PMID: 32973949; PMCID: PMC7507020.

23. Zhukova E., Myshkova E. The effectiveness of the introduction of the updated treatment regimens and microbiological diagnostics MDR/XDR tuberculosis. European Respiratory Journal, 2019, vol. 54, s. 63, pp. 2657.